About SciNeuro
SciNeuro is a company based in Shanghai (China) founded in 2020 by Min Li.. SciNeuro has raised $153 million across 3 funding rounds from investors including General Atlantic, Arch Venture Partners and Lilly Asia Ventures. SciNeuro offers products and services including SNP614, SNP210, SNP201, SNP318, and SNP234. SciNeuro operates in a competitive market with competitors including Nura Bio, Healx, Cingulate, STALICLA and PaxMedica, among others.
- Headquarter Shanghai, China
- Founders Min Li
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$153 M (USD)
in 3 rounds
-
Latest Funding Round
$53 M (USD), Series A
Dec 04, 2025
-
Investors
General Atlantic
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SciNeuro
SciNeuro offers a comprehensive portfolio of products and services, including SNP614, SNP210, SNP201, SNP318, and SNP234. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Downregulates LRRK2 protein to address Parkinson's disease pathology.
Targets TDP-43 aggregates for ALS and frontotemporal dementia treatment.
Binds pathogenic alpha-synuclein in Parkinson's and related disorders.
Inhibits Lp-PLA2 to repair blood-brain barrier in Alzheimer's disease.
Removes beta-amyloid aggregates to slow Alzheimer's progression.
Restores progranulin levels for frontotemporal dementia management.
Unlock access to complete
Unlock access to complete
Funding Insights of SciNeuro
SciNeuro has successfully raised a total of $153M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $53 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $53.0M
-
First Round
First Round
(09 Dec 2020)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2025 | Amount | Series A - SciNeuro | Valuation | Arch Venture Partners , LAV |
|
| Nov, 2025 | Amount | Grant - SciNeuro | Valuation |
investors |
|
| Dec, 2020 | Amount | Series A - SciNeuro | Valuation | Lilly Asia Ventures , Arch Venture Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in SciNeuro
SciNeuro has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include General Atlantic, Arch Venture Partners and Lilly Asia Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Boyu Capital is recognized as a leading alternative asset management firm.
|
Founded Year | Domain | Location | |
|
Private equity fund focused on global markets
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by SciNeuro
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - SciNeuro
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Scineuro Comparisons
Competitors of SciNeuro
SciNeuro operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nura Bio, Healx, Cingulate, STALICLA and PaxMedica, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Diagnostic solutions and neuroprotective medicines for neurological disorders are provided.
|
|
| domain | founded_year | HQ Location |
AI-powered drug discovery platform for rare diseases is developed.
|
|
| domain | founded_year | HQ Location |
Cingulate is focused on developing treatments for ADHD and anxiety.
|
|
| domain | founded_year | HQ Location |
Precision medicines for neurodevelopmental disorders are manufactured using DEPI technology.
|
|
| domain | founded_year | HQ Location |
Drugs for neurodevelopmental disorders are developed by PaxMedica.
|
|
| domain | founded_year | HQ Location |
Drugs are developed to treat multiple neurological disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Scineuro
Frequently Asked Questions about SciNeuro
When was SciNeuro founded?
SciNeuro was founded in 2020.
Where is SciNeuro located?
SciNeuro is headquartered in Shanghai, China.
Who is the current CEO of SciNeuro?
Min Li is the current CEO of SciNeuro. They have also founded this company.
Is SciNeuro a funded company?
SciNeuro is a funded company, having raised a total of $153M across 3 funding rounds to date. The company's 1st funding round was a Series A of $100M, raised on Dec 09, 2020.
What does SciNeuro do?
SciNeuro was established in 2020 and is headquartered in Shanghai, China. Focus is placed on the development of therapeutic solutions targeting central nervous system disorders within the biotechnology sector. Operations involve research and innovation in CNS treatments, with services extending to potential clinical applications. The company is led by Founder and CEO Min Li, emphasizing advancements in neurological therapies.
Who are the top competitors of SciNeuro?
What products or services does SciNeuro offer?
SciNeuro offers SNP614, SNP210, SNP201, SNP318, and 2 more products and services.
Who are SciNeuro's investors?
SciNeuro has 8 investors. Key investors include General Atlantic, Arch Venture Partners, Lilly Asia Ventures, Boyu, and Sequoia Capital.